122 related articles for article (PubMed ID: 16183464)
21. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.
Banta-Green CJ; Maynard C; Koepsell TD; Wells EA; Donovan DM
Addiction; 2009 May; 104(5):775-83. PubMed ID: 19344438
[TBL] [Abstract][Full Text] [Related]
22. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS).
Ross J; Teesson M; Darke S; Lynskey M; Ali R; Ritter A; Cooke R
Drug Alcohol Rev; 2005 Sep; 24(5):411-8. PubMed ID: 16298835
[TBL] [Abstract][Full Text] [Related]
23. Socio-demographic and clinical characteristics of 3129 heroin users in the first methadone maintenance treatment clinic in China.
Du WJ; Xiang YT; Wang ZM; Chi Y; Zheng Y; Luo XN; Cai ZJ; Ungvari GS; Gerevich J
Drug Alcohol Depend; 2008 Apr; 94(1-3):158-64. PubMed ID: 18164146
[TBL] [Abstract][Full Text] [Related]
24. Controlled trial of prescribed heroin in the treatment of opioid addiction.
March JC; Oviedo-Joekes E; Perea-Milla E; Carrasco F;
J Subst Abuse Treat; 2006 Sep; 31(2):203-11. PubMed ID: 16919749
[TBL] [Abstract][Full Text] [Related]
25. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of human immunodeficiency virus and its association with hepatitis B, C, and D virus infections among incarcerated male substance abusers in Taiwan.
Chu FY; Chiang SC; Su FH; Chang YY; Cheng SH
J Med Virol; 2009 Jun; 81(6):973-8. PubMed ID: 19382252
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan.
Lee TS; Shen HC; Wu WH; Huang CW; Yen MY; Wang BE; Chuang P; Shih CY; Chou YC; Liu YL
Subst Abuse Treat Prev Policy; 2011 Apr; 6():6. PubMed ID: 21473789
[TBL] [Abstract][Full Text] [Related]
28. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV.
Kresina TF; Bruce RD; Cargill VA; Cheever LW
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S83-8. PubMed ID: 16265621
[TBL] [Abstract][Full Text] [Related]
29. Intravenous and intranasal heroin-dependent treatment-seekers: characteristics and treatment outcome.
Highfield DA; Schwartz RP; Jaffe JH; O'Grady KE
Addiction; 2007 Nov; 102(11):1816-23. PubMed ID: 17784892
[TBL] [Abstract][Full Text] [Related]
30. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.
Shi J; Zhao LY; Copersino ML; Fang YX; Chen Y; Tian J; Deng Y; Shuai Y; Jin J; Lu L
Eur J Pharmacol; 2008 Jan; 579(1-3):160-6. PubMed ID: 17977528
[TBL] [Abstract][Full Text] [Related]
31. Referral for chronic hepatitis C treatment from a drug dependency treatment setting.
Hallinan R; Byrne A; Agho K; Dore GJ
Drug Alcohol Depend; 2007 Apr; 88(1):49-53. PubMed ID: 17067763
[TBL] [Abstract][Full Text] [Related]
32. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine replacement therapy: a confirmed benefit.
Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
[TBL] [Abstract][Full Text] [Related]
34. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection.
Hagan H; Strauss SM; Astone JM; Des Jarlais DC
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S297-303. PubMed ID: 15768338
[TBL] [Abstract][Full Text] [Related]
35. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.
Cacoub P; Rosenthal E; Halfon P; Sene D; Perronne C; Pol S
J Viral Hepat; 2006 Oct; 13(10):678-82. PubMed ID: 16970599
[TBL] [Abstract][Full Text] [Related]
36. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia.
Maher L; Li J; Jalaludin B; Wand H; Jayasuriya R; Dixon D; Kaldor JM
Drug Alcohol Depend; 2007 Jul; 89(2-3):244-50. PubMed ID: 17289299
[TBL] [Abstract][Full Text] [Related]
37. Assessment of alcohol use among methadone maintenance patients by direct ethanol metabolites and self-reports.
Wurst FM; Dürsteler-MacFarland KM; Auwaerter V; Ergovic S; Thon N; Yegles M; Halter C; Weinmann W; Wiesbeck GA
Alcohol Clin Exp Res; 2008 Sep; 32(9):1552-7. PubMed ID: 18616663
[TBL] [Abstract][Full Text] [Related]
38. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users.
Neaigus A; Gyarmathy VA; Zhao M; Miller M; Friedman SR; Des Jarlais DC
J Infect Dis; 2007 Apr; 195(7):1052-61. PubMed ID: 17330797
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of hepatitis C infection in injecting drug users in Zadar County, Croatia.
Medić A; Dzelalija B; Sonicki Z; Zekanović D
Coll Antropol; 2008 Sep; 32(3):697-702. PubMed ID: 18982740
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoid negative feedback in methadone-maintained former heroin addicts with ongoing cocaine dependence: dose-response to dexamethasone suppression.
Aouizerate B; Ho A; Schluger JH; Perret G; Borg L; Le Moal M; Piazza PV; Kreek MJ
Addict Biol; 2006 Mar; 11(1):84-96. PubMed ID: 16759341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
